LSP leads 21m round into Neurent Medical
Irish life sciences company Neurent Medical has closed a 21m Series B investment co-led by LSP as well as Atlantic Bridge with participation of Fountain Healthcare Partners.
Author Archive for: TG
About Thomas Gabrielczyk
This author has yet to write their bio.
Meanwhile lets just say that we are proud Thomas Gabrielczyk contributed a whooping 484 entries.
Entries by
Janssen presents one-shot COVID-19 vaccine data
19th January 2021 in News /by Thomas GabrielczykJ&J subsidiary Janssen Pharma has presented updated Phase I/II antibody levels supporting a single shot administration for its COVID-19 vaccine.
German researchers find reason for remdesivir’s inefficiency
14th January 2021 in News /by Thomas GabrielczykGerman Researchers have unraveled how remdesivir interferes with the viral RNA polymerase and why it does not block SARS-CoV-2 completely.
LSP reports first closing of dementia fund
13th January 2021 in News /by Thomas GabrielczykEuropean life sciences investors LSP has closed a new fund to fight dementia at 50m.
Valneva in talks with EU about 60 million vaccine doses
12th January 2021 in News /by Thomas GabrielczykFrench Valneva SE announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine, VLA2001.
Immunocore bags US$75m in Series C round
12th January 2021 in News /by Thomas GabrielczykImmuno-oncology specialist Immunocore plc announced the completion of a $75m Series C private financing round.
EU approves second COVID-19 vaccine
7th January 2021 in News /by Thomas GabrielczykFollowing a recommendation by the European Medicines Agency (EMA), the European Commission has approved a second vaccine against the novel coronavirus SARS-CoV-2.
Angelini Pharma to take over Arvelle Therapeutics
6th January 2021 in News /by Thomas GabrielczykItalian Angelini Pharma and Swiss CNS disease specialist Arvelle Therapeutics have entered into a definitive merger agreement.
COVID-19 test gives results within minutes
5th January 2021 in News /by Thomas GabrielczykUniversity of Birmingham researchers have invented a COVID-19 RNA test that reduces testing time from 30 minutes to under five, and delivers accurate results.
EMA greenlights BioNtech’s COVID-19 vaccine
22nd December 2020 in News /by Thomas GabrielczykFollowing a rapid FDA approval, the European drug authority EMA has recommended to conditionally approve BioNTechs mRNA vaccine BNT162b2 in the EU.